Search Results - "Mäenpää, J."

Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry by Veskimäe, K., Staff, S., Grönholm, A., Pesu, M., Laaksonen, M., Nykter, M., Isola, J., Mäenpää, J.

“…Targeting Poly (ADP-ribose) polymerase 1 (PARP-1) involved in base excision repair (BER) has been shown to be a clinically effective treatment strategy in…”
Get full text

Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma by Lagerstedt, Maria, Huotari-Orava, R., Nyberg, R., Nissinen, L., Farshchian, M., Laasanen, S.-L., Snellman, E., Mäenpää, J. U., Kähäri, V.-M.

“…Purpose The two main etiological factors for vulvar squamous cell carcinoma (vSCC) are the vulvar dermatosis lichen sclerosus (LS) and high-risk human…”
Get full text

Toremifene for premenstrual mastalgia: a randomised, placebo‐controlled crossover study by Oksa, S, Luukkaala, T, Mäenpää, J

“…Objective  To investigate the efficacy of toremifene in the treatment of premenstrual mastalgia. Design  Double‐blind, placebo‐controlled crossover study…”
Get full text

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial by Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., Harter, P.

“…In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly…”
Get full text

Inhibition and induction of human cytochrome P450 (CYP) enzymes by PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., RAUNIO, H.

“…Previously, the study of induction and inhibition of drug metabolism was largely empirical and phenomenological, and prediction beyond the compounds under…”
Get full text

Docetaxel: promising and novel combinations in ovarian cancer by Mäenpää, J U

“…Despite considerable progress over the past two decades in the management of advanced ovarian cancer, the majority of patients with this type of malignancy…”
Get full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer by Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp

“…When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a…”
Get full text

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease by Wilson, M.K., Pujade-Lauraine, E., Aoki, D., Mirza, M.R., Lorusso, D., Oza, A.M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S.-J., Ferrero, A.M., Edmondson, R.J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., Ochiai, K.

“…This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC),…”
Get full text

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer by Mirza, M.R., Tandaric, L., Henriksen, J.R., Mäenpää, J., Christensen, R.D., Waldstrøm, M., Lindemann, K., Roed, H., Auranen, A., Akslen, L.A., Thomsen, L.C.V., Lindberg, S.N., Madsen, K., Bjørge, L.

“…In patients with epithelial ovarian cancer (EOC), the clinical efficacy of monotherapy with immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 is modest…”
Get full text

Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial by Falconer, Henrik, Palsdottir, Kolbrun, Stalberg, Karin, Dahm-Kähler, Pernilla, Ottander, Ulrika, Lundin, Evelyn Serreyn, Wijk, Lena, Kimmig, Rainer, Jensen, Pernille Tine, Zahl Eriksson, Ane Gerda, Mäenpää, Johanna, Persson, Jan, Salehi, Sahar

“…Radical hysterectomy with pelvic lymphadenectomy represents the standard treatment for early-stage cervical cancer. Results from a recent randomized controlled…”
Get more information

Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies by Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M, Visakorpi, T, Mäenpää, J, Ungureanu, D, Staff, S

“…Ovarian cancer has the highest mortality rate of all gynecologic malignancies. Identification of new biomarkers is highly needed due to its late diagnosis and…”
Get full text

Toremifene: where do we stand? by Mäenpää, J, Holli, K, Pasanen, T

“…Toremifene is a chlorinated triphenylethylene that is indicated for postmenopausal breast cancer. For advanced disease, toremifene has been found to be as…”
Get full text

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line by Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

“…Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall…”
Get full text

Severe hypoglycaemia in children and adolescents during multiple-dose insulin therapy by Tupola, S., Rajantie, J., Mäenpää, J.

“…Episodes of severe hypoglycaemia, resulting in coma and/or convulsions, were documented in an unselected, population‐based group of 376 children and…”
Get full text

Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers by ERLUND, I, KOSONEN, T, ALFTHAN, G, MÄENPÄÄ, J, PERTTUNEN, K, KENRAALI, J, PARANTAINEN, J, ARO, A

“…Quercetin is a flavonoid with a wide range of biological activities. It mainly occurs in plants as glycosides, such as rutin (quercetin rutinoside) in tea…”
Get full text

Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome (LS): a descriptive study by Kalamo, Mari H., Mäenpää, J. U., Seppälä, T. T., Mecklin, J. P., Huhtala, H., Sorvettula, K., Pylvänäinen, K., Staff, S.

“…To prevent endometrial carcinoma in Lynch syndrome (LS), regular gynecological surveillance visits and prophylactic surgery are recommended. Previous data have…”
Get full text

Preoperative assessment of endometrial carcinoma by three‐dimensional power Doppler angiography by Saarelainen, S. K., Vuento, M. H., Kirkinen, P., Mäenpää, J. U.

“…Objective Preoperative evaluation of the depth of myometrial invasion in endometrial carcinoma is challenging. The objective of this study was to evaluate the…”
Get full text

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial by Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A, Pujade-Lauraine, E

“…Background: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial…”
Get full text

Reduction in ERRα is associated with lichen sclerosus and vulvar squamous cell carcinoma by Lagerstedt, M, Huotari-Orava, R, Nyberg, R, Mäenpää, J.U, Snellman, E, Laasanen, S.-L

“…Abstract Objective ERRs (estrogen-related receptors) regulate energy metabolism, the cell cycle and inflammatory processes in both normal and cancer cells…”
Get full text

A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen by Mattsson, L.-Å., Skouby, S. O., Heikkinen, J., Vaheri, R., Mäenpää, J., Timonen, U.

“…Objective To compare bleeding control, efficacy and safety of two dose-ranging continuous combined hormone replacement therapy (HRT) regimens with those of a…”
Get full text